Clinical experience of long-term observation of the efficacy of a fixed combination of insulin glargine and GLP-1RA lixisenatide in patients with type 2 diabetes mellitus who did not reach the target glycemia values with the use of oral antidiabetic drugs

Background. Almost half (47.8%) of patients with type 2 diabetes mellitus (DM2) do not reach glycated hemoglobin (HbA1c) levels of less than 7% and, accordingly, are at high risk for chronic complications of this disease, including macrovascular complications and mortality from them, because HbA1c is one of the most significant predictors of myocardial infarction and acute stroke among DM2 patients. Despite success in treating patients with DM, the issue of long-term and sustainable compensation for diabetes remains relevant. In 2018, a fixed combination of the basal insulin analogue glargine 100 U/ml and the prandial glucagon-like peptide type 1 receptor agonist (GLP-1RA) lixisenatide became available in Russia. As shown in the LixiLan-O clinical study, a fixed combination of insulin glargine and lixisenatide allows 74% of patients who have not previously reached treatment goals with oral antidiabetic drugs to achieve an HbA1c level of less than 7%. Description of the clinical case. This publication presents a clinical case of successful long-term (more than a year) use of this drug by DM2 patients who did not reach the target glycemic values with oral antidiabetic drugs. Conclusion. On the example of DM2 patient, it was shown that the fixed combination of the basal insulin analogue glargine and arGPP-1 lixisenatide in real clinical practice demonstrates the efficacy and safety parameters previously shown in clinical trials.

type 2 diabetes mellitus, glycated hemoglobin, fixed combinations, lixisenatide, glargine, glycemic control, insulin therapy